Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 5, 2007, Pages 941-951

  Smith, Peter J ^a   Olson, Jon A ^a   Constable, David ^a   Schwartz, Julie ^b   Proffitt, Richard T ^c   Adler Moore, Jill P ^a  

^a CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

^c RichPro Associates   (United States)

Author keywords

Antifungal agents; Bioavailability; Candidiasis; Lipid formulations

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; DRUG ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DBA 2 MOUSE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RETENTION; DRUG TISSUE LEVEL; FEMALE; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULE EPITHELIUM; LIVER; LUNG; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PROVOCATION TEST; SPLEEN;

AMPHOTERICIN B; ANIMALS; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; FEMALE; KIDNEY; LIPOSOMES; MICE; MICE, INBRED DBA; SPLEEN;

EID: 34447577731     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm077     Document Type: Article

References (44)

1. Wiederhold NP, Tam VH, Chi J et al. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50: 469-73.
2. Andes D, Safdar N, Marchillo K et al. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006; 50: 674-84.
3. Jones BL, McLintock LA. Impact of diagnostic markers on early antifungal therapy. Curr Opin Infect Dis 2003; 16: 521-6.
4. Boswell GW, Buell D, Bekersky K. AmBisome (liposomal amphotericin B): A comparative review. J Clin Pharmacol 1998; 38: 583-92.
5. Olson JA, Adler-Moore JP, Schwartz JJ et al. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006; 50: 2122-31.
6. Meunier F, Prentice HG, Ringdén O et al. Liposomal amphotericin B (AmBisome): Safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991; 28 Suppl B: 83-91.
7. Walsh TJ, Yeldandi V, McEvoy M et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998; 42: 2391-8.
8. Wingard JR, White MH, Anaissie E et al. A randomized, doubleblind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000; 31: 1155-63.
9. Ringdén O, Meunler F, Tollemar J et al. Efficacy of amphotericin B B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28 Suppl B: 73-82.
10. Prentice HG, Hann IM, Hebrecht R et al. A randomized oomparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-8.
11. Walsh TJ, Finberg RW, Amdt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71.
12. Leenders ACAP, Reiss P, Portegies P et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11: 1463-71.
13. Johnson PC, Wheat LJ, Cloud GA et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patents with AIDS. Ann Intern Med 2002; 137: 105-9.
14. Comely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): A randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial). Blood 2005; 106: 3222 (ASH Annual Meeting Abstracts).
15. Fortun J, Martin-Davila P, Moreno S et al. Prevention of invasive fungal infections in liver transplant recipients: The role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 2003; 52: 813-9.
16. Tollemar J, Hockerstedt K, Ericzon BG et al. Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: Long term results of a randomized, placebo-controlled trial. Transplant Proc 1995; 27: 1195-8.
17. Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163-8.
18. Garcia A, Adler-Moore JP, Proffitt RT et al. Single-dose AmBisome (liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis. Antimicrob Agents Chemother 2000; 44: 2327-32.
19. Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr Opin Investig Drugs 2003; 4: 179-85.
20. Shadomy S, McCay JA, Schwartz SI et al. Bioassay for hamycin and amphotericin B in serum and other biological fluids. Appl Microbiol 1969; 17: 497-503.
21. Olson JA, Adler-Moore JP, Smith PJ et al. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005; 49: 4895-902.
22. Graybill JR, Bocanegra R, Luther M et al. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob Agents Chemother 1997; 41: 1937-9.
23. Leunk RD, Moon RJ. Physiological and metabolic alterations accompanying systemic candidiasis in mice. Infect Immun 1979; 26: 1035-41.
24. Van Rooijen N, Kors N, van den Ende M et al. Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell Tissue Res 1990; 260: 215-22.
25. Takemoto K, Yamamoto Y, Ueda Y et al. Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans. Microbiol Immunol 2006; 50: 579-86.
26. Andes D, Stamsted T, Conklin R et al. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001; 45: 922-6.
27. Cuenca-Estrella M, Gomez-Lopez A, Mellado E et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-21.
28. Espinel-Ingroff A, Fothergill A, Peter J et al. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3204-8.
29. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51.
30. Comely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
31. van Burik JA, Ratanatharathom V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-16.
32. Gumbo T, Drusano GL, Liu W et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007; 51: 968-74.
33. Allen SD, Sorensen KN, Nejdl MJ et al. Prophylactic efficacy of aerolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994; 34: 1001-13.
34. BitMansour A, Brown JM. Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation. J Infect Dis 2002; 186: 134-7.
35. Spellberg B, Schwartz J, Fu Y et al. Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother 2006; 58: 973-9.
36. Leenders ACAP, de Marie S, ten Kate MT et al. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. J Antimicrob Chemother 1996; 38: 215-25.
37. Groll AH, Mickiene D, Petraitis R et al. Disposition and efficacy of amphotericin B formulations in a kidney target model of invasive candidiasis. In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract J-1607, p. 389. American Society for Microbiology, Washington, DC, USA.
38. Sperry PJ, Cua DJ, Wetzel SA et al. Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cells. Med Mycol 1998; 36: 135-41.
39. Diekema DJ, Messer SA, Hollis RJ et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: 3623-6.
40. Takemoto K, Yamamoto Y, Ueda Y et al. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. J Antimicrob Chemother 2006; 57: 724-31.
41. Abra RM, Hunt CA. Liposome disposition in vivo. III. Dose and vesicle-size effects. Biochim Biophys Acta 1981; 666: 493-503.
42. Bosworth ME, Hunt CA. Liposome disposition in vivo II: Dose dependency. J Pharm Sci 1982; 71: 100-4.
43. Heinemann V, Bosse D, Jehn U et al. Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure. J Antimicrob Chemother 1997; 40: 295-7.
44. Vogelsinger H, Weiler S, Djanani A et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother 2006; 57: 1153-60.